Epithelial Ovarian Cancer—Varied Treatment Results

Author:

Millert-Kalińska Sonja12ORCID,Przybylski Marcin2,Pruski Dominik2ORCID,Stawicka-Niełacna Małgorzata3,Mądry Radosław4

Affiliation:

1. Doctoral School, Poznan University of Medical Sciences, 61-701 Poznań, Poland

2. Department of Obstetrics and Gynecology, District Public Hospital in Poznan, 60-479 Poznań, Poland

3. Department of Clinical Genetics and Pathology, University of Zielona Góra, 65-046 Zielona Góra, Poland

4. Department of Oncology, Poznan University of Medical Sciences, 60-569 Poznań, Poland

Abstract

Ovarian cancer (OC) is the eighth most common cancer worldwide and is usually diagnosed in advanced stages. Despite many available data, no treatment results have been reviewed in Poland. This study enrolled 289 first-time patients treated between 2018 and 2021 by the Department of Oncology of the Poznań University of Medical Sciences (SKPP). The relationships among starting treatment in our centre, the type of first intervention, and the final decision were significant (p < 0.001). Patients in the SKPP group were more likely to primarily have a laparoscopy and less likely to have an exploratory laparotomy. Neoadjuvant chemotherapy (NACT) after a laparotomy was less often a final decision among SKPP patients (9% vs. 22%), in contrary to NACT after a laparoscopy (23% vs. 4%). Factors affecting the shortening of progression-free survival (PFS) were an advanced stage of the disease, a histopathological diagnosis, the type of cytoreduction, and the final decision. Significance according to the final decision was revealed for PDS vs. NACT after a laparotomy (p < 0.001) and for PDS vs. NACT after a laparoscopy (p = 0.011). Our study supports the benefits of treating ovarian cancer in an oncology centre with a high patient throughput. Further observations might also answer the question about overall survival (OS).

Publisher

MDPI AG

Subject

Health Information Management,Health Informatics,Health Policy,Leadership and Management

Reference23 articles.

1. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020;Cabasag;Int. J. Cancer,2022

2. Epidemiology of ovarian cancer;Adriana;Chin. Clin. Oncol.,2020

3. Didkowska Joanna, W.U. (2021). Zachorowania i Zgony na Nowotwory Złośliwe w Polsce, Krajowy Rejestr Nowotworów, Centrum Onkologii, Instytut im. Marii Skłodowskiej–Curie.

4. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update;Berek;Int. J. Gynecol. Obstet.,2021

5. Hosmer, D.W., Lemeshow, S., and Sturdivant, R.X. (2013). Applied Logistic Regression, John Wiley & Sons, Inc.. [3rd ed.].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3